DDInter781 DDInter905
Fosinopril is a phosphinic acid-containing ester prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly hydrolyzed to fosinoprilat, its principle active metabolite. Fosinoprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Fosinopril may be used to treat mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.
Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability.
Fosinopril {u} (Compound) resembles {v} (Compound) Lisinopril
Lisinopril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Fosinopril {u} (Compound) resembles {v} (Compound) Lisinopril
Lisinopril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Asparaginase Escherichia coli
Asparaginase Escherichia coli {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Fosinopril {u} (Compound) resembles {v} (Compound) Spirapril
Spirapril {u} (Compound) resembles {v} (Compound) Lisinopril
Lisinopril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Fosinopril {u} (Compound) resembles {v} (Compound) Lisinopril
Lisinopril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Prednisolone
Prednisolone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Fosinopril {u} (Compound) resembles {v} (Compound) Ramipril
Ramipril {u} (Compound) resembles {v} (Compound) Moexipril
Moexipril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Fosinopril {u} (Compound) resembles {v} (Compound) Spirapril
Spirapril {u} (Compound) resembles {v} (Compound) Quinapril
Quinapril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Fosinopril {u} (Compound) resembles {v} (Compound) Enalapril
Enalapril {u} (Compound) resembles {v} (Compound) Lisinopril
Lisinopril {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Fosinopril {u} (Compound) treats {v} (Disease) hypertension
hypertension {u} (Disease) is treated by {v} (Compound) Nicardipine
Nicardipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Fosinopril {u} (Compound) binds {v} (Gene) SLC15A1
SLC15A1 {u} (Gene) is bound by {v} (Compound) Valganciclovir
Valganciclovir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Fosinopril {u} (Compound) upregulates {v} (Gene) SYNGR3
SYNGR3 {u} (Gene) is upregulated by {v} (Compound) Vinblastine
Vinblastine {u} may lead to a major life threatening interaction when taken with {v} Idelalisib
Fosinopril (Compound) resembles Lisinopril (Compound) and Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Fosinopril (Compound) resembles Lisinopril (Compound) and Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Fosinopril (Compound) resembles Spirapril (Compound) and Spirapril (Compound) resembles Lisinopril (Compound) and Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Fosinopril (Compound) resembles Lisinopril (Compound) and Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Fosinopril (Compound) resembles Ramipril (Compound) and Ramipril (Compound) resembles Moexipril (Compound) and Moexipril may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Fosinopril (Compound) resembles Spirapril (Compound) and Spirapril (Compound) resembles Quinapril (Compound) and Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Fosinopril (Compound) resembles Enalapril (Compound) and Enalapril (Compound) resembles Lisinopril (Compound) and Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Fosinopril (Compound) treats hypertension (Disease) and hypertension (Disease) is treated by Nicardipine (Compound) and Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Fosinopril (Compound) binds SLC15A1 (Gene) and SLC15A1 (Gene) is bound by Valganciclovir (Compound) and Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Fosinopril (Compound) upregulates SYNGR3 (Gene) and SYNGR3 (Gene) is upregulated by Vinblastine (Compound) and Vinblastine may lead to a major life threatening interaction when taken with Idelalisib